Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.

Greenberg Traurig Further Strengthens Pharmaceutical, Medical Device & Health Care Practice

Retrieved on: 
星期五, 十一月 19, 2021

Isidro will focus her practice at Greenberg Traurig on pharmaceutical, medical device, and consumer products litigation, including mass torts and MDLs.

Key Points: 
  • Isidro will focus her practice at Greenberg Traurig on pharmaceutical, medical device, and consumer products litigation, including mass torts and MDLs.
  • About Greenberg Traurig's Pharmaceutical, Medical Device, & Health Care Practice: Greenberg Traurig's Pharmaceutical, Medical Device & Health Care Practice includes more than 90 trial attorneys representing clients in complex litigation in courts across the country.
  • About Greenberg Traurig's Products Liability & Mass Torts Litigation Practice: The Products Liability & Mass Torts Litigation Practice is an integral part of Greenberg Traurig's 600-plus member global Litigation Practice.
  • About Greenberg Traurig: Greenberg Traurig, LLP (GT) has approximately 2300 attorneys in 40 locations in the United States, Latin America, Europe, Asia, and the Middle East.

Liquidia Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
星期三, 十一月 3, 2021

MORRISVILLE, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the quarter and nine-months ended September 30, 2021.

Key Points: 
  • These pre-approval inspections were completed in August 2021 and October 2021, respectively.
  • More recently in October 2021, the PTAB ruled in Liquidias favor in the IPR proceeding against U.S. Patent No.
  • Revenue recognized during 2021 related primarily to the promotion agreement with Sandoz Inc., after the acquisition of Liquidia PAH in November 2020.
  • The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC.

Lex Machina Launches Legal Analytics for False Claims Act Litigation

Retrieved on: 
星期二, 十月 5, 2021

MENLO PARK, Calif., Oct. 5, 2021 /PRNewswire/ -- Lex Machina and LexisNexis recently released the new False Claims Module, which provides Legal Analytics for litigation involving the False Claims Act (the "FCA"), as well as related claims under state law.

Key Points: 
  • MENLO PARK, Calif., Oct. 5, 2021 /PRNewswire/ -- Lex Machina and LexisNexis recently released the new False Claims Module, which provides Legal Analytics for litigation involving the False Claims Act (the "FCA"), as well as related claims under state law.
  • The False Claims Module includes cases in which the federal or state government, or a relator on behalf of the government, alleges a violation of the False Claims Act or an equivalent false claims state statute.
  • "Many of our customers have expressed a strong interest in seeing Legal Analytics on False Claims cases," said Ellen Chen, Legal Data Analyst and False Claims practice area lead at Lex Machina.
  • Based in Silicon Valley, Lex Machina is part of LexisNexis, a leading global provider of legal, regulatory, and business information and analytics.

Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...

Retrieved on: 
星期一, 八月 30, 2021

Migraine affects over a billion people worldwide1, and its impact is felt by patients, caregivers, and society as a whole all around the world.

Key Points: 
  • Migraine affects over a billion people worldwide1, and its impact is felt by patients, caregivers, and society as a whole all around the world.
  • Migraine does not discriminate, and well discuss disparities in headache medicine across diverse populations during our Meet the Expert session.
  • Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials.
  • Adverse Reactions: The most common adverse reactions in clinical trials (5% and greater than placebo) were injection site reactions.

Program Update: The National Children's Cancer Society and Fosun Pharma Partner to Help Patients in Guatemala

Retrieved on: 
星期五, 八月 20, 2021

Through the Michele Hertlein Global Outreach Program , the NCCS works with pharmaceutical companies to distribute donated cancer treatment drugs and medical supplies worldwide.

Key Points: 
  • Through the Michele Hertlein Global Outreach Program , the NCCS works with pharmaceutical companies to distribute donated cancer treatment drugs and medical supplies worldwide.
  • Fosun Pharma assisted with the request, and 1,680 vials of Voriconazole were sent to the hospital at no charge saving the facility nearly $134,000 in costs.
  • Fosun Pharma USA Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., a leading innovation-driven global pharmaceutical and healthcare group.
  • The NCCS and the hospital in Guatemala are thankful that Fosun Pharma provided desperately needed help.

Liquidia Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
星期二, 八月 10, 2021

ET

Key Points: 
  • ET
    MORRISVILLE, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the quarter ended June 30, 2021.
  • The Company will host a webcast and conference call at 8:30 a.m. Eastern Daylight Time to discuss the second quarter financial results and provide a corporate update.
  • Damian deGoa, Liquidias Chief Executive Officer, said: We continue to execute on our corporate priorities and strengthen the companys position.
  • On June 2, 2021, the FDA accepted for review the New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder.